JRNLclub, the online journal club

View Original

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.

Nat Med. 2019 Dec;25(12):1938-1947.

Khan S1, Zhang X2, Lv D1, Zhang Q3, He Y1, Zhang P2, Liu X1, Thummuri D1, Yuan Y1, Wiegand JS1, Pei J1, Zhang W4, Sharma A5, McCurdy CR2, Kuruvilla VM3, Baran N3, Ferrando AA6, Kim YM7, Rogojina A8, Houghton PJ8, Huang G9, Hromas R9, Konopleva M3, Zheng G10, Zhou D11.

  1. Department of Pharmacodynamics, University of Florida, Gainesville, FL, USA.
  2. Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA.
  3. Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
  4. Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
  5. Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA.
  6. Department of Pediatrics, Pathology, Cell Biology and Systems of Biology and Institute for Cancer Genetics, Columbia University, New York, NY, USA.
  7. Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA, USA.
  8. Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
  9. Department of Medicine, the Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
  10. Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA. zhengg@cop.ufl.edu.
  11. Department of Pharmacodynamics, University of Florida, Gainesville, FL, USA. zhoudaohong@cop.ufl.edu.

Presented by Sajid Khan